Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions

Current Opinion in Allergy and Clinical Immunology

Volumn 2, Issue 4, 2002, Pages 307-315

  Reilly, Timothy P ^a   Ju, Cynthia ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cutaneous drug reactions; Idiosyncratic drug toxicity; Keratinocytes; Skin; Sulfonamides

Indexed keywords

HAPTEN; SULFAMETHOXAZOLE; SULFONAMIDE; ANTIINFECTIVE AGENT;

DRUG ACTIVATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; HUMAN; IMMUNOREGULATION; KERATINOCYTE; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN MANIFESTATION; DRUG ERUPTION; IMMUNOLOGY;

ANTI-INFECTIVE AGENTS; DRUG ERUPTIONS; HUMANS; SULFONAMIDES;

EID: 0036675227     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200208000-00004     Document Type: Review

References (103)

1. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996; 15:9-50.
2. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev 2001; 53:357-379. This is a recent, comprehensive review of the many issues related to CDRs.
3. Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129:466-468.
4. Carr A, Vasak E, Munro V, et al. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin Exp Immunol 1994; 97:260-265.
5. Barbaud AM, Bene MC, Reichert-Penetrat S, et al. Immunocompetent cells and adhesion molecules in 14 cases of cutaneous drug reactions induced with the use of antibiotics. Arch Dermatol 1998; 134:1040-1041.
6. Yawalkar N, Egli F, Hari Y, et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30:847-855.
7. Yawalkar N, Shrikhande M, Hari Y, et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106:1171-1176.
8. Yawalkar N, Pichler WJ. Pathogenesis of drug-induced exanthema. Int Arch Allergy Immunol 2001; 124:336-338. This work expands on previous in-vitro studies showing that infiltrating T cells during a CDR have cytotoxic potential and produce significantly higher amounts of interleukin-5 and interferon-γ.
9. Hari Y, Frutig-Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001; 31:1398-1408. This study suggests an important correlation between the predominant activation of particular T-cell classes (CD4 versus CD8) and the type of drug reaction. Most interesting are the findings that HLA expression is increased in patients with bullous and hepatic involvement, and that CD8+ T-cell predominance correlates with the noted development of hepatic injury.
10. Choquet-Kastylevsky G, Intrator L, Chenal C, et al. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol 1998; 139:1026-1032.
11. Hertl M, Jugert F, Merk HF. CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995; 132:215-220.
12. Cribb AE, Spielberg SP, Griffin GP. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995; 23:406-414.
13. Rieder MJ, Uetrecht J, Shear NH, Spielberg SP. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther 1988; 244:724-728.
14. Cribb AE, Nuss CE, Alberts DW, et al. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 1996; 9:500-507.
15. Naisbitt DJ, Hough SJ, Gill HJ, et al. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999; 126:1393-1407.
16. Meekins CV, Sullivan TJ, Gruchalla RS. Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 1994; 94:1017-1024.
17. Daftarian MP, Filion LG, Cameron W, et al. Immune response to sulfamethoxazole in patients with AIDS. Clin Diagn Lab Immunol 1995; 2:199-204.
18. Gill HJ, Hough SJ, Naisbitt DJ, et al. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J Pharmacol Exp Ther 1997; 282:795-801.
19. Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105:179-184.
20. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the 'danger hypothesis' and innate immune system. Chem Res Toxicol 1999; 12:387-395.
21. Reilly TP, Lash LH, Doll MA, et al. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000; 114:1164-1173.
22. Rubin RL, Kretz-Rommel A. Phagocyte-mediated oxidation in idiosyncratic adverse drug reactions. Curr Opin Hematol 2001; 8:34-40.
23. Buhl R, Jaffe HA, Holroyd KJ, et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989; 2:1294-1298.
24. Naisbitt DJ, Vilar FJ, Stalford AC, et al. Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res Hum Retroviruses 2000; 16:1929-1938.
25. Baron JM, Holler D, Schiffer R, et al. Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol 2001; 116:541-548. Together with [26], these studies provide the most recent analyses of the expression of a variety of drug-metabolizing enzymes and drug transporters in human keratinocytes.
26. Janmohamed A, Dolphin CT, Phillips IR, Shephard EA. Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem Pharmacol 2001; 62:777-786.
27. Barker JN, Mitra RS, Griffiths CE, et al. Keratinocytes as initiators of inflammation. Lancet 1991; 337:211-214.
28. Stoof FJ, Boorsma DM, Nickoloff BJ. Keratinocytes and immunological cytokines. In: Leigh L, Lane E, Watt F, editors. The keratinocyte handbook. Cambridge, UK: Cambridge University Press; 1994. pp. 365-399.
29. Albanesi C, Cavani A, Girolomoni G. Interferon-gamma-stimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II molecules. J Invest Dermatol 1998; 110:138-142.
30. Barker JN, Sarma V, Mitra RS, et al. Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest 1990; 85:605-608.
31. Teraki Y, Moriya N, Shiohara T. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am J Pathol 1994; 145:550-560.
32. Haas J, Lipkow T, Mohamadzadeh M, et al. Induction of inflammatory cytokines in murine keratinocytes upon in vivo stimulation with contact sensitizers and tolerizing analogues. Exp Dermatol 1992; 1:76-83.
33. Barker JN, Jones ML, Mitra RS, et al. Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 1991; 139:869-876.
34. Homey B, Alenius H, Muller A, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8:157-165. This study demonstrates that keratinocytes from patients with various cutaneous inflammatory diseases produce increased amounts of the chemokine CCL27, which can be induced by TNF-α and interleukin-1β. CCL27 then binds to CCR10 on circulating T cells, therein providing a homing mechanism for T cells to enter the cutaneous compartment.
35. Britschgi M, Steiner UC, Schmid S, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107:1433-1441. This study shows the heterogeneous distribution of drug-specific CD4/CD8 phenotypes, T-cell receptor expression, and cytokine/chemokine profiles from patients with various CDRs. Interestingly, the data suggest that these varied characteristics may translate into different clinical manifestations of CDR.
36. Nickoloff BJ, Mitra RS, Green J, et al. Activated keratinocytes present bacterial-derived superantigens to T lymphocytes: relevance to psoriasis. J Dermatol Sci 1993; 6:127-133.
37. Huber H, Descossy P, van Brandwijk R, Knop J. Activation of murine epidermal TCR-gamma delta+ T cells by keratinocytes treated with contact sensitizers. J Immunol 1995; 155:2888-2894.
38. Nakano Y. Antigen-presenting cell function of epidermal cells activated by hapten application. Br J Dermatol 1998; 138:786-794.
39. Ansel J, Perry P, Brown J, et al. Cytokine modulation of keratinocyte cytokines. J Invest Dermatol 1990; 94(Suppl):101S-107S.
40. Villada G, Roujeau JC, Clerici T, et al. Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol 1992; 128:50-53.
41. Schnyder B, Mauri-Hellweg D, Zanni M, et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997; 100:136-141.
42. Zanni MP, von Greyerz S, Schnyder B, et al. HLA-restricted, processing, and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998; 102:1591-1598.
43. von Greyerz S, Zanni MP, Frutig K, et al. Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta+ T cell clones. J Immunol 1999; 162:595-602.
44. Schnyder B, Burkhart C, Schnyder-Frutig K, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000; 164:6647-6654.
45. Burkhart C, von Greyerz S, Depta JP, et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and surfamethoxazole-metabolite-specific human CD4+ T-cells. Br J Pharmacol 2001; 132:623-630. These experiments demonstrate a unique specificity of individual T-cell clones from patients with a previous sulfonamide-induced CDR to sulfamethoxazole or its chemically reactive metabolite SMX-NO. The ability of glutathione to significantly inhibit T-cell reactivity to SMX-NO supports its unique detoxifying role.
46. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002; 109:295-299. A recent review of costimulation and its effects on immune responsiveness.
47. Matzinger P. Essay 1: the Danger model in its historical context. Scand J Immunol 2001; 54:4-9.
48. Todryk SM, Melcher AA, Dalgleish AG, Vile RG. Heat shock proteins refine the danger theory. Immunology 2000; 99:334-337.
49. Li Z, Menoret A, Srivastava P. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 2002; 14:45-51. This is a recent overview of the critical immunological functions of heat shock proteins.
50. Wakem P, Burns Jr RP, Ramirez F, et al. Allergens and irritants transcriptionally upregulate CD80 gene expression in human keratinocytes. J Invest Dermatol 2000; 114:1085-1092.
51. Nickoloff BJ, Mitra RS, Green J, et al. Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. J Immunol 1993; 150:2148-2159.
52. Nickoloff BJ, Turka LA. Keratinocytes and the danger model. Science 1996; 273:1479-1480.
53. Vance RE. Cutting edge: cutting edge commentary: a Copernican revolution? Doubts about the danger theory. J Immunol 2000; 165:1725-1728.
54. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 1249-1255.
55. Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci USA 2000; 97:14590-14595.
56. Gill HJ, Tjia JF, Kitteringham NR, et al. The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Pharmacogenetics 1999; 9:43-53.
57. Riley RJ, Cribb AE, Spielberg SP. Glutathione transferase mu deficiency is not a marker for predisposition to sulphonamide toxicity. Biochem Pharmacol 1991; 42:696-698.
58. Zielinska E, Niewiarowski W, Bodalski J, et al. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants. Pharm World Sci 1998; 20:123-130.
59. Pirmohamed M, Alfirevic A, Vilar J, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with cotrimoxazole hypersensitivity. Pharmacogenetics 2000; 10:705-713.
60. Wolkenstein P, Loriot MA, Aractingi S, et al. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS. Pharmacogenetics 2000; 10:821-828.
61. Cribb AE, McQuaid T, Renton KW. Effect of lipopolysaccharide (LPS)-evoked host defense activation on hepatic microsomal formation and reduction of sulfamethoxazole hydroxylamine in the rat. Biochem Pharmacol 2001; 62:457-459. These data suggest a unique mechanism by which bacterial infection may decrease detoxification capability, and therein potentially increase susceptibility to sulfamethoxazole-induced adverse drug reactions.
62. Choquet-Kastylevsky G, Santolaria N, Tedone R, et al. Induction of delayed-type hypersensitivity to sulfamethoxazole in mice: role of metabolites. Toxicol Lett 2001; 119:183-192. This is the first in-vivo demonstration of an immune-mediated reaction to sulfonamides. These data, along with those presented by Naisbitt et al. [63], provide important support for the critical role of reactive metabolite formation in the development of cutaneous toxicity.
63. Naisbitt DJ, Gordon SF, Pirmohamed M, et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001; 133:295-305. Together with [62], this study provides strong evidence to support the dependence of cellular immune reactivity in vivo on reactive metabolite formation and haptenation of cellular proteins. It also suggests the existence of other critical factors that seem to be necessary for the development of toxicity.
64. von Greyerz S, Bultemann G, Schnyder K, et al. Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. Int Immunol 2001; 13:877-885. This report shows a wide diversity of drug-specific T cells, and suggests a unique autoimmune-type reactivity of drug-specific T cells based on their unusually high cross-reactivity with non-self-MHC-peptide complexes.
65. Ozkaya-Bayazit E, Akar U. Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol 2001; 45:712-717. This paper provides the first evidence linking sulfonamide-induced CDRs with a particular HLA haplotype.
66. Blanca M, Posadas S, Torres MJ, et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. Allergy 2000; 55:998-1004.
67. Reiss Y, Proudfoot AE, Power CA, et al. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001; 194:1541-1547.
68. Dhabhar FS, Satoskar AR, Bluethmann H, et al. Stress-induced enhancement of skin immune function: a role for gamma interferon. Proc Natl Acad Sci USA 2000; 97:2846-2851.
69. Bourdi M, Masubuchi Y, Reilly TP, et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 2002; 35:289-298. This study demonstrates a key role for the endogenously produced, anti-inflammatory cytokine interleukin-10 in limiting drug-induced liver injury. The data suggest that polymorphisms in interleukin-10 and other protective factors may serve as susceptibility factors for drug toxicity.
70. Smoller BR, Krueger J. Detection of cytokine-induced protein gamma-immune protein-10 (gamma-IP10) in atypical melanocytic proliferations. J Am Acad Dermatol 1991; 25:627-631.
71. Pichler WJ, Zanni M, von Greyerz S, et al. High IL-5 production by human drug-specific T cell clones. Int Arch Allergy Immunol 1997; 113:177-180.
72. Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev 2000; 174:21-34.
73. Nickoloff BJ, Turka LA. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol Today 1994; 15:464-469.
74. Reilly TP, Brady JN, Marchick MR, et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001; 14:1620-1628. Comparable to the overall theme of [69], this study demonstrates an important protective function of endogenously produced mediators, in this case cyclooxygenase-2 derived mediators, that respond to drug-induced tissue injury to limit the extent of damage.
75. Craven NM, Jackson CW, Kirby B, et al. Cytokine gene polymorphisms in psoriasis. Br J Dermatol 2001; 144:849-853.
76. Hess DA, O'Leary EF, Lee JT, et al. Inhibition of cytokine production and interference in IL-2 receptor-mediated Jak-Stat signaling by the hydroxylamine metabolite of sulfamethoxazole. FASEB J 2001; 15:1855-1857. This article provides evidence to support the immunomodulatory effects of SMX-NOH, with implications for immune-based drug reactions in vivo that are secondary to alterations in normal immune function.
77. Goodman RE, Nestle F, Naidu YM, et al. Keratinocyte-derived T cell costimulation induces preferential production of IL-2 and IL-4 but not IFN-gamma. J Immunol 1994; 152:5189-5198.
78. Rubin RL, Kretz-Rommel A. A nondeletional mechanism for central T-cell tolerance. Crit Rev Immunol 2001; 21:29-40.
79. Aithal PG, Daly AK, Chen Y, Day CP. Promoter polymorphism of IL-10 and IL-4 predict risk of diclofenac-induced hepatitis [Abstract]. Gastroenterology 2000; 118:1071.
80. Grove J, Daly AK, Bassendine MF, et al. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000; 46:540-545.
81. Asadullah K, Eskdale J, Wiese A, et al. Interleukin-10 promoter polymorphism in psoriasis. J Invest Dermatol 2001; 116:975-978.
82. Pirmohamed M, Lin K, Chadwick D, Park BK. TNF alpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001; 56:890-896. This is the first study to demonstrate an association between CDRs and polymorphic expression of inflammatory mediators.
83. Puig L, Fernandez-Figueras MT, Ferrandiz C, et al. Epidermal expression of 65 and 72 kd heat shock proteins in psoriasis and AIDS-associated psoriasiform dermatitis. J Am Acad Dermatol 1995; 33:985-989.
84. Breloer M, Dorner B, More SH, et al. Heat shock proteins as 'danger signals': eukaryotic Hsp60 enhances and accelerates antigen-specific IFN-gamma production in T cells. Eur J Immunol 2001; 31:2051-2059. This is one of the more recent studies showing that heat shock proteins, which themselves can be induced by the stress of reactive drug species, can enhance immune responsiveness.
85. Merrill JE, Koyanagi Y, Chen IS. Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol 1989; 63:4404-4408.
86. von Sydow M, Sonnerborg A, Gaines H, Strannegard O. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991; 7:375-380.
87. Rautonen J, Rautonen N, Martin NL, et al. Serum interleukin-6 concentrations are elevated and associated with elevated tumor necrosis factor-alpha and immunoglobulin G and A concentrations in children with HIV infection. AIDS 1991; 5:1319-1325.
88. Schnyder B, Frutig K, Mauri-Hellweg D, et al. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 1998; 28:1412-1417.
89. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134:710-714.
90. Graziosi C, Pantaleo G, Fauci AS. Comparative analysis of constitutive cytokine expression in peripheral blood and lymph nodes of HIV-infected individuals. Res Immunol 1994; 145:602-605.
91. Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 1998; 161:1659-1663.
92. Mohamadzadeh M, Berard F, Essert G, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 2001; 194:1013-1020.
93. Sadlack B, Lohler J, Schorle H, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995; 25:3053-3059.
94. Carr A, Swanson C, Penny R, Cooper DA. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993; 167:180-185.
95. Gougeon ML, Poccia F, Boullier S. Human gamma delta T lymphocytes in HIV disease: effector functions and control by natural killer cell receptors. Springer Semin Immunopathol 2000; 22:251-263.
96. Boismenu R, Havran WL. An innate view of gamma delta T cells. Curr Opin Immunol 1997; 9:57-63.
97. Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000; 18:423-449.
98. Pullen H, Wright N, Murdoch JM. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 1967; 2:1176-1178.
99. Suzuki Y, Inagi R, Aono T, et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1998; 134:1108-1112.
100. Turgeon NA, Iwakoshi NN, Phillips NE, et al. Viral infection abrogates CD8(+) T-cell deletion induced by costimulation blockade. J Surg Res 2000; 93:63-69.
101. Buchweitz JP, Ganey PE, Bursian SJ, Roth RA. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 2002; 300:460-467. This is the first in-vivo demonstration, in an experimental setting, that nontoxic doses of a drug can be made toxic in combination with underlying endotoxemia. The data provide important support for the assertion that concomitant infection may increase susceptibility to adverse drug events.
102. Larregina AT, Morelli AE, Spencer LA, et al. Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol 2001; 2:1151-1158.
103. Sayeh E, Uetrecht JP. Factors that modify penicillamine-induced autoimmunity in Brown Norway rats: failure of the Th1/Th2 paradigm. Toxicology 2001; 163:195-211.